F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer: prediction of response to therapy

Stuart Suttie; Dympna McAteer; Margaret Sheehan; Marianne Nicolson; Lutz Schweiger; Solveig Hammonds; Timothy Smith; Andrew Welch; Kenneth Park

doi:10.4021/wjon2010.04.201w

F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer: prediction of response to therapy

Stuart Suttie
, Dympna McAteer
, Margaret Sheehan
, Marianne Nicolson
, Lutz Schweiger
, Solveig Hammonds
, Timothy Smith
, Andrew Welch
, Kenneth Park

University of Dundee

Research output: Contribution to journal › Article › peer-review

15 Downloads (Pure)

Abstract

Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival).

Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined.

Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation.

Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.

Original language	English
Pages (from-to)	66-77
Number of pages	12
Journal	World Journal of Oncology
Volume	1
Issue number	2
DOIs	https://doi.org/10.4021/wjon2010.04.201w
Publication status	Published - Apr 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

positron emission tomography
esophageal cancer
F-18-FDG
C-11-choline
response

Access to Document

10.4021/wjon2010.04.201w

F-18-FDG and C-11-choline
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/3.0/
Final published version, 674 KB

Cite this

@article{3a6c78f2d3ad45dc841a50dd2f216cfc,

title = "F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer: prediction of response to therapy",

abstract = "Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.",

keywords = "positron emission tomography, esophageal cancer, F-18-FDG, C-11-choline, response",

author = "Stuart Suttie and Dympna McAteer and Margaret Sheehan and Marianne Nicolson and Lutz Schweiger and Solveig Hammonds and Timothy Smith and Andrew Welch and Kenneth Park",

year = "2010",

month = apr,

doi = "10.4021/wjon2010.04.201w",

language = "English",

volume = "1",

pages = "66--77",

journal = "World Journal of Oncology",

issn = "1920-4531",

publisher = "Elmer Press",

number = "2",

}

TY - JOUR

T1 - F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer

T2 - prediction of response to therapy

AU - Suttie, Stuart

AU - McAteer, Dympna

AU - Sheehan, Margaret

AU - Nicolson, Marianne

AU - Schweiger, Lutz

AU - Hammonds, Solveig

AU - Smith, Timothy

AU - Welch, Andrew

AU - Park, Kenneth

PY - 2010/4

Y1 - 2010/4

N2 - Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.

AB - Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.

KW - positron emission tomography

KW - esophageal cancer

KW - F-18-FDG

KW - C-11-choline

KW - response

U2 - 10.4021/wjon2010.04.201w

DO - 10.4021/wjon2010.04.201w

M3 - Article

SN - 1920-4531

VL - 1

SP - 66

EP - 77

JO - World Journal of Oncology

JF - World Journal of Oncology

IS - 2

ER -

F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer: prediction of response to therapy

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this